This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Enzo Biochem Receives Approval For Novel Blood Based Test For Colorectal Cancer Risk

Enzo Biochem, Inc. (NYSE:ENZ) today announced that the New York State Department of Health has approved Enzo Clinical Labs’ use of the ColonSentry™ test for providing an assessment of a patient’s risk of having colorectal cancer. The ColonSentry™ test was originally developed by GeneNews (TSX: GEN) and requires only a small blood sample which can be collected during a routine blood draw. Enzo plans to begin offering the assay to its clientele in March 2012.

The ColonSentry™ test uses RNA contained in blood to measure the level of the expression of seven genes. These genes serve as biomarkers whose levels can reflect the current presence or severity of a disease state. Interpretation of the status of these seven biomarkers can allow physicians to identify patients who have an increased current risk of having colorectal cancer. The test requires only a small sample of blood and can thus be easily incorporated as a pre-screening measure into routine yearly physical exams.

“The approval of this assay underscores the execution of our strategic plan to build our company into a unique developer and provider of high value molecular and esoteric products and services”, said Barry Weiner, President of Enzo Biochem. "By utilizing the technological and assay development expertise of our Life Sciences group along with the translational medicine capabilities we have built at Enzo Clinical Labs, we have been able to develop a robust pipeline of products and technologies designed for today’s healthcare market. We expect to announce additional developments arising from Enzo’s unique integrated operating structure in the weeks ahead. Presently, Enzo Biochem is the only lab in the US that is approved to offer this assay.”

"With respect to ColonSentry™, we can now provide physicians with a new tool for their patients in assessing their risk for having colorectal cancer with a simple blood test. The information provided by this test can guide their recommendation for a colonoscopy. We know that patient compliance for colonoscopies is low—the ColonSentry™ test is a non-invasive method that provides strong guidance to recommend a colonoscopy. Evidence supported recommendations can lead to higher compliance, potentially contributing to earlier detection of colorectal cancer and fewer deaths,” he added.

1 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,119.57 -53.11 -0.31%
S&P 500 1,991.31 -2.98 -0.15%
NASDAQ 4,530.4470 +2.7580 0.06%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs